Search
Ivermectin
go.drugbank.com/drugs/DB00602ApprovedInvestigationalVet approved[L36763,A238929] In addition, the use of aggregate patient data in large-scale meta-analyses (as opposed to individual patient data (IPD)) has been shown to disguise otherwise blatant data errors, such … While studies are still ongoing, much of the evidence for ivermectin in COVID-19 relies on pre-print _in vitro_ data, and the clinical utility of this data remains unclear.
Mixtures: Heartgard Plus Chewable Tablet for Dogs - Up to 25 lbs, Eqvalan Duo Oral Paste for HorseCategories: Compounds used in a research, industrial, or household settingTemsirolimus
go.drugbank.com/drugs/DB06287ApprovedInvestigationalTemsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007. … Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel.
Products: Torisel Concentrate for Injection 25mg/mL, TORISEL 25 MG/ML IV INFUZYONLUK COZELTI ICEREN FLAKON, 1 ADETTheophylline
go.drugbank.com/drugs/DB00277ApprovedInvestigationalTheophylline is marketed under several brand names such as Uniphyl and Theochron, and it is indicated mainly for asthma, bronchospasm, and COPD.
Mixtures: Theophylline in Dextrose, Theophylline in DextroseCategories: Drugs for Obstructive Airway DiseasesHuman C1-esterase inhibitor
go.drugbank.com/drugs/DB06404ApprovedInvestigationalThe disease is characterized by acute attacks of painful, and in some cases, fatal swelling of several soft tissues or edema, which may last up to five days when untreated.[L16586, L16606] … [L16586, L16606] This drug is indicated for prophylaxis and treatment of Hereditary Angioedema (HAE), a human genetic disorder caused by a shortage of C1 inhibitor activity that results in an overreaction
Synonyms: C1-INHCategories: Drugs Used in Hereditary AngioedemaMedulloblastomas
go.drugbank.com/conditions/DBCOND0032185Drugs: CarmustineSynonyms: Medulloblastoma, no International Classification of Diseases for Oncology subtype, Medulloblastoma, no ICD-O subtypeCetirizine
go.drugbank.com/drugs/DB00341ApprovedInvestigationalThe prevalence of allergic rhinitis in the United States is about 15% according to physician diagnoses, and up to 30%, according to self-reported nasal symptoms. … One of the most common uses for this drug is for a condition called _allergic rhinitis_.
Mixtures: FORT-GRIP, VERACETAM NF CAPSULASCategories: Antihistamines for Systemic Use, Histamine H1 Antagonists, Non-SedatingCisatracurium
go.drugbank.com/drugs/DB00565ApprovedInvestigationalCisatracurium is a non-depolarising neuromuscular blocking agent of the benzylisoquinolinium class, available in its salt form, cisatracurium besylate. … [A243416,A253592] Cisatracurium is an R-cis-R-cis isomer of [atracurium] and has approximately 3 times its neuromuscular blocking potency.
Synonyms: Cisatracurium ion, (1r,2r,1'r,2'r)-2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium]Products: Atrax Inj Cisatracurium Besylate Injection, USP Solution for Injection or Infusion 2 mg/ml, Cisatracurium Kabi 2 mg/ml solution for injection or infusionOxycodone
go.drugbank.com/drugs/DB00497ApprovedIllicitInvestigational[A178696] It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics … for an extended period.
Mixtures: OXYCODON/NALOXON-NX 10/5, OXYCODON/NALOXON-NX 10/5Categories: Heterocyclic Compounds with 4 or More Rings, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeArginine
go.drugbank.com/drugs/DB00125ApprovedInvestigationalNutraceuticalAn essential amino acid that is physiologically active in the L-form.
International brands: R-Gene 10Mixtures: Cardiotek-RX, AMINOSTERIL N-HEPA FOR INTRAVENOUS INFUSION 8%Azacitidine
go.drugbank.com/drugs/DB00928ApprovedInvestigational[A1415] The use of oral azacitidine for the treatment of AML in patients in complete remission was approved by the FDA in September 2020.[L35335] … [A1406,A1413,A1415] Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity.
Products: Azacitidine For, Vidaza powder for suspension for injection 100mg/vial